GSK Announces Additional Layoffs of 150 Employees in Cambridge, MA Amid Vaccine Manufacturing Relocation

Jul 23, 2025 17:29 CST Updated 17:29

GSK

Pharmaceutical R&D Manufacturer

Biospace reported yesterday that, according to the Worker Adjustment and Retraining Notification (WARN) Act announcement, GSK layoffs are continuing, and the pharmaceutical company will lay off 150 employees in Cambridge, Massachusetts.

According to Endpoints News, this London-based company plans to relocate its Streptococcus pneumoniae vaccine production line from Cambridge to Marietta, Pennsylvania.

Last October, GSK announced an investment of $800 million to expand R&D and commercial facilities at its Marietta site. The upgrade includes the establishment of a vaccine manufacturing plant for products based on its star technology, MAPS (Multiple Antigen Presenting System), which aims to elicit stronger immune responses against various specific bacteria. GSK acquired this technology through the 2022 acquisition of Affinivax.

This round of layoffs will last from October 4 this year to March 31 next year, marking the second wave of layoffs announced by GSK this month.

According to a report by Fierce Biotech last week, GSK will also cut members of its global R&D team, with the specific number unknown.

Source: biospace, Medicine Ladder

Let's have a vote and talk about your thoughts onUnderstanding Compliance~

ClickRead the original text and participate in the vote~